Mixing a trendy drug for a global health problem like obesity with a demand that far exceeds the supply cooks up a recipe too good for counterfeiters to ignore. That’s the problem patients are facing with Novo Nordisk A/S’ semaglutide products, Ozempic and Wegovy, which have been in short supply all over the world since early last year due to significant, and unexpected, demand for weight management.

Novo Nordisk A/S will this month launch its weekly weight loss glucagon-like peptide-1 injection Wegovy (semaglutide) at the same monthly cost as its older daily shot Saxenda (liraglutide), following FDA approval in overweight and obese adults.